Please login to the form below
safety
This page shows the latest safety news and features for those working in and with pharma, biotech and healthcare.
Finch Therapeutics bags $53m for microbiome therapies
The biotech is currently enrolling a phase 2 study evaluating the safety and efficacy of its therapy in adults with ASD. ... Difficile infections. It is currently enrolling patients in its PUNCH CD 3 phase 3 study to evaluate the safety and efficacy
Latest news
-
FDA rejects Sarepta’s new Duchenne drug over safety fears
Sarepta has an ongoing randomised double-blind, placebo-controlled study, ESSENCE, which is assessing the efficacy and safety of golodirsen and casimersen, which should provide more robust data on whether these
-
UK no longer measles-free as vaccination rates fall dramatically
There has been increasing global scepticism around the safety and efficacy of vaccines, with WHO now naming ‘vaccine hesitancy’ as one of the top ten threats to global health in 2019.
-
AbbVie scores FDA approval for arthritis treatment upadacitinib
However, there have been some safety concerns regarding the class, with the FDA releasing new safety data on Xeljanz earlier this year which showed that the drug could increase the risks
-
Leaked no-deal Brexit document forecasts widespread shortages
with potential harm to animal health and welfare, the environment and wider food safety and availability, as well as, in the case of zoonotic diseases, posing a risk to human health’.
-
Potential cure for Ebola following trial success
The trial was monitored by an independent data and safety monitoring board, which has recommended the study be stopped and that all future patients receive either REGN0EB3 or mAB114.
More from news
Approximately 84 fully matching, plus 1,996 partially matching documents found.
Latest Intelligence
-
The Cystic Fibrosis Buyers’ Club
The Club has also taken great care to independently verify the quality and safety of the imported medicines, paying for NHS-run labs to confirm the bio-equivalence tests run by
-
Streamlining clinical trials – why better data use is key
Compliance requirements are in place to ensure patient safety when a drug ultimately comes to market. ... endpoints and patient safety, which can lead to better data, faster enrolment and reduced patient burdens.”.
-
A new EU in the making, what lies ahead for pharma?
and Food Safety policies.
-
Biotech profile: Tom Evans, CEO, Vaccitech.
As many of the safety and manufacturing issues surrounding our MVA-NP M1 vaccine are already de-risked, a positive efficacy readout in the challenge study should allow us to take
-
Women Leaders in UK Healthcare: Liz Henderson
She joined Merck in 2009, initially as European Environmental Health &Safety Director for the company’s life sciences business sector and subsequently became Site Director for Merck’s manufacturing plant in
More from intelligence
Approximately 2 fully matching, plus 140 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
Officially joining the biopharma on 1 October, Schuermans will play a part in bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety
-
Immodulon Therapeutics bolsters senior team
clinical research, medical affairs and drug safety.
-
Prof Sir Mike Richards joins Incisive Health as senior counsel
In his most recent role Sir Mike led the inspection, quality and safety agenda for hospitals and prior to that he served in senior clinical roles at NHS England and the
-
Eli Lilly appoints senior VP for corporate affairs and communications
Institute for Highway Safety.
-
Frequency Therapeutics appoints Steven Dworetzky
Machanda will continue to lead development activities including formulation and analytical development, manufacturing and non-clinical safety studies to facilitate clinical trials and broaden the drug development pipeline.
More from appointments
Approximately 0 fully matching, plus 49 partially matching documents found.
Latest from PMHub
-
Behaviour change – is there something missing?
It already invests hugely in long-term development programmes to understand drug efficacy and safety; the step required to take the same long-term view on implementing behaviour change programmes is
-
Planning a pharma exhibition stand? You must read this!
For example, Health &Safety and installation policies from the venue. Developing a marketing plan to reach your potential customers, communicate the messages you want to share, and boost your presence at ... Submitting all plans and Health &Safety
-
What does it mean to be an agile organisation
institutions. PA: There might be pressure to react, for example a takeover threat, a share price drop or a drug safety issue.
-
MIT reveals new pill to deliver insulin
We’ve looked closely into this and the safety of the device.
-
Am I wrong to be apprehensive about gene therapy?
Professor Klamroth also highlighted that there are still a number of unknowns remaining regarding the long-term safety and efficacy of gene therapy.
More from PMHub
Approximately 4 fully matching, plus 70 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Dovetail
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
